An immunofluorescence-based assay has been developed to evaluate the target antigen of six-transmembrane epithelial antigen of prostate 1 (STEAP1) on CTCs in metastatic castration-resistant prostate cancer patients (59). The gene discussed is STEAP1; the disease is Familial prostate cancer.